This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment

Описание

Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate, were recently guests on Benzinga's All Access. Cingulate is a biotechnology company developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, relieving the pill burden many people with chronic conditions suffer. Cingulate was just given clearance by the FDA to seek full approval for its lead candidate, CTx-1301.